TG Therapeutics, Inc.

Report azionario NasdaqCM:TGTX

Capitalizzazione di mercato: US$5.6b

TG Therapeutics Crescita futura

Criteri Future verificati 3/6

Si prevede che TG Therapeutics aumenterà gli utili e i ricavi rispettivamente del 15.9% e 23.5% all'anno, mentre si prevede che l'EPS crescerà del 12.4% all'anno.

Informazioni chiave

15.9%

Tasso di crescita degli utili

12.38%

Tasso di crescita dell'EPS

Biotechs crescita degli utili25.4%
Tasso di crescita dei ricavi23.5%
Rendimento futuro del capitale proprion/a
Copertura analitica

Good

Ultimo aggiornamento14 May 2026

Aggiornamenti recenti sulla crescita futura

Recent updates

Aggiornamento della narrazione • May 21

TGTX: Execution Risks And Lower P/E Assumptions Will Pressure Future Upside

Narrative Update on TG Therapeutics The updated analyst price target for TG Therapeutics moves slightly lower to about $17.46 from roughly $17.57 as analysts adjust their assumptions on revenue growth, profit margins and future P/E, while still reflecting recent Street research that includes a $10 upward revision from H.C. Wainwright. Analyst Commentary Behind the modest adjustment in the average price target to about $17.46, bearish analysts remain focused on execution risks and how those could affect the valuation that investors are willing to pay for TG Therapeutics.
Aggiornamento della narrazione • Apr 29

TGTX: JPMorgan Cut And Execution Risks Will Pressure Future Upside Potential

Analysts have modestly raised their fair value estimate for TG Therapeutics to about $17.57 per share, from roughly $17.32, citing refreshed assumptions around revenue growth, profit margins, discount rates and future P/E, as well as recent Street research including the latest JPMorgan price target update. Analyst Commentary Recent Street research, including a reduced price target at JPMorgan, points to a more cautious tone around TG Therapeutics, even as fair value estimates move only slightly.
Seeking Alpha • Apr 19

TG Therapeutics: Flawless Execution And $500 Million Non-Dilutive Capital Bolster Outlook

Summary TG Therapeutics is downgraded from Strong Buy to Buy after a 17% rally, reflecting a now fairer valuation. Briumvi IV continues to gain market share in MS, while the SC version’s trial is fully enrolled and could double the addressable market. Management guides conservatively for 2026 Briumvi U.S. net revenue of $825–$850 million and maintains disciplined operating expense targets. TGTX enhances financial flexibility with a $750 million term loan, expanded buybacks, and no equity dilution, supporting ongoing growth initiatives. Read the full article on Seeking Alpha
Aggiornamento della narrazione • Apr 15

TGTX: Recent JPMorgan Cut Will Likely Expose Fragile Earnings Expectations

Analysts have adjusted their fair value estimate for TG Therapeutics from $15.49 to $17.32, reflecting updated assumptions around the discount rate, revenue growth, profit margin, and future P/E following recent price target revisions, including the $3 cut highlighted by JPMorgan. Analyst Commentary Recent commentary around TG Therapeutics has tilted cautious, with the $3 price target cut at JPMorgan reinforcing a more conservative stance on both execution and valuation risk.
Aggiornamento della narrazione • Mar 31

TGTX: Shares Should Advance As Durable Multiple Sclerosis Data Supports Recovery

Narrative Update The blended analyst price target for TG Therapeutics is now effectively unchanged around $44, as recent moves, including a $3 trim at one firm and modest raises at others, reflect updated views on sector funding conditions, deal activity, and regulatory risk, while leaving core assumptions on growth, margins, and future P/E largely intact. Analyst Commentary Recent Street research around TG Therapeutics has been active but mixed, with one major firm trimming its target while others lift theirs, leaving the blended target roughly unchanged.
Aggiornamento della narrazione • Mar 17

TGTX: Shares Should Rebound As Long Term Multiple Sclerosis Data Drives Confidence

Analysts recently adjusted their price targets for TG Therapeutics in a mixed way, with one firm cutting its target by $3 while others raised theirs by $2 and $2. These changes reflect updated views on sector conditions, access to capital, M&A activity and company specific data catalysts.
Aggiornamento della narrazione • Mar 03

TGTX: Shares Should Rebound As Long Term Multiple Sclerosis Data Supports Upside

Analysts have nudged their price targets on TG Therapeutics in both directions recently, with moves such as a $3 trim at one firm and a $2 lift at another. These changes reflect updated views on discount rates, revenue growth assumptions, profit margins and future P/E, rather than a wholesale shift in the $44.43 fair value estimate used in this model.
Aggiornamento della narrazione • Feb 17

TGTX: Shares Should Rebound As Revenue Outlook Supports Mixed Street Views

Analysts have made only a modest adjustment to their TG Therapeutics price targets, reflecting a slightly higher assumed discount rate and marginally lower future P/E expectations, while maintaining a consistent fair value estimate near $44 per share. Analyst Commentary Recent Street research on TG Therapeutics has been mixed, with some firms lifting price targets and others trimming them.
Aggiornamento della narrazione • Feb 02

TGTX: Shares Should Rebound As Mixed Street Views Contrast With Strong Revenue Outlook

Analysts have adjusted their blended price target on TG Therapeutics slightly lower, trimming fair value by about $0.43 to reflect updated assumptions around growth, margins and future P/E following a mix of recent target revisions from major firms. Analyst Commentary Recent Street research on TG Therapeutics reflects a mix of optimism on the setup for biotech and specific caution around the company’s execution and valuation, which is feeding into the modest trim in the blended price target.
Aggiornamento della narrazione • Jan 19

TGTX: Shares Should Rebound As Revenue Outlook Strengthens On Updated Guidance

Narrative Update Analysts have nudged their price target for TG Therapeutics higher to about $44.86, up from roughly $44.29. This reflects updated earnings models that incorporate slightly higher profit margin assumptions, a modestly adjusted discount rate and a small change to expected future P/E levels following recent Street research, including target increases from BofA, Goldman Sachs and JPMorgan.
Aggiornamento della narrazione • Jan 05

TGTX: Higher JPMorgan Price View Will Likely Overstate Future Earnings Delivery

TG Therapeutics' analyst price target has moved higher, with a recent US$3 increase to US$49 as analysts refreshed their models after the latest earnings update. Analyst Commentary The latest move to a US$49 price target from JPMorgan signals that at least one major firm has refreshed its view following the recent earnings update, with a focus on updated assumptions in its valuation model.
Aggiornamento della narrazione • Dec 22

TGTX: Higher Earnings Visibility Will Support A Re-Rating Over Time

Analysts have lifted their price target on TG Therapeutics shares, raising fair value by about $7 per share to $60, as updated post earnings models factor in a higher future P/E multiple despite slightly lower growth and margin assumptions. Analyst Commentary Following the latest earnings update, bullish analysts are increasingly highlighting TG Therapeutics as a beneficiary of improving fundamentals and greater earnings visibility, which they see as supporting a higher valuation range over the medium term.
Aggiornamento della narrazione • Dec 08

TGTX: Shares Will Likely Rebound As Long Term Sales Milestone Approaches

Analysts have modestly raised their blended price target for TG Therapeutics, reflecting increased confidence in multi year Briumvi growth and updated post earnings models that point to a path toward more than $1 billion in annual sales. Analyst Commentary Recent Street updates reflect a predominantly constructive stance on TG Therapeutics, with upwardly revised price targets and reinforced positive ratings following the latest earnings update.
Aggiornamento della narrazione • Nov 24

TGTX: Shares Will Likely Rebound Following Recent Buyback And Earnings Dip

Analysts have raised their price targets for TG Therapeutics, with recent updates reflecting increases of $3 to $49 and $2 to $55. This is based on confidence in ongoing sales growth and an improved margin outlook following the company's earnings report.
Aggiornamento della narrazione • Nov 05

TGTX: Shares Will Likely See Renewed Momentum With Expanding U.S. Drug Adoption

Analysts have modestly increased their price target for TG Therapeutics, raising it from approximately $43.57 to $44.29. This adjustment is due to optimism about multi-year sales growth for Briumvi and updated post-earnings forecasts.
Articolo di analisi • Oct 23

TG Therapeutics (NASDAQ:TGTX) Takes On Some Risk With Its Use Of Debt

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Aggiornamento della narrazione • Oct 22

Analyst Commentary Drives Optimism for TG Therapeutics as Briumvi Growth Fuels Higher Price Targets

Narrative Update on TG Therapeutics Analysts have raised their price target for TG Therapeutics by $2 to $55. They cite expectations for sustained multi-year sales growth, supported by strong prospects for Briumvi in the U.S. market.
Aggiornamento della narrazione • Oct 08

A Subcutaneous Launch Will Unlock The Anti-CD20 MS Market

Analysts have raised their price target for TG Therapeutics from $40.50 to $43.57, citing expectations of sustained Briumvi sales growth and an improved revenue outlook. Analyst Commentary Recent Street research highlights a range of perspectives regarding TG Therapeutics, with particular focus on Briumvi's market performance and growth trajectory.
Articolo di analisi • Sep 30

What TG Therapeutics, Inc.'s (NASDAQ:TGTX) 26% Share Price Gain Is Not Telling You

TG Therapeutics, Inc. ( NASDAQ:TGTX ) shareholders would be excited to see that the share price has had a great month...
Articolo di analisi • Jul 29

Revenues Not Telling The Story For TG Therapeutics, Inc. (NASDAQ:TGTX)

You may think that with a price-to-sales (or "P/S") ratio of 13.6x TG Therapeutics, Inc. ( NASDAQ:TGTX ) is a stock to...
Seeking Alpha • Mar 14

TG Therapeutics: Bright Outlook, Bolstered By Briumvi And Upcoming Trials

Summary TG Therapeutics is rated a strong buy with a 12-month price target of $44, driven by positive Briumvi sales and future trial plans. Briumvi exceeded FY 2024 sales forecasts and is expected to surpass the $525M goal for FY 2025, with promising patient enrollment trends. Upcoming pivotal trials and potential label updates for Briumvi, including subcutaneous administration, could enhance patient convenience and treatment efficacy. TG Therapeutics' strong cash position and ongoing Briumvi revenues are expected to fund operations and potential portfolio expansion, despite risks from trial data and international approvals. Read the full article on Seeking Alpha
Seeking Alpha • Nov 05

TG Therapeutics: Modest Q3 Sales Beat, Focus Shifts To Early 2025 Updates

Summary TG Therapeutics, Inc. reported a modest Q3 beat and raised the full-year net sales guidance range for Briumvi by $7.5 million at the mid-point. The results were slightly underwhelming but generally in line with management expectations of a softer Q3. Now we wait for the important updates in early 2025 — preliminary Q4 net sales of Briumvi, the guidance for 2025, and the preliminary results from subcutaneous Briumvi's trial. I expect the FY 2025 net sales guidance range to be at or slightly below the analyst consensus as the company sets the stage to beat and raise throughout the year. The company set expectations for a once every two-month dosing schedule for subcutaneous Briumvi, and I would consider quarterly dosing a clear win. Read the full article on Seeking Alpha
User avatar
Nuova narrazione • Sep 04

BRIUMVI's Breakthrough In MS Market Promises Robust Revenue Surge And Expanding Therapeutic Horizons

Strong sales of BRIUMVI and strategic expansions such as innovative versions aim to secure market dominance in treating relapsing multiple sclerosis.
Seeking Alpha • Aug 07

TG Therapeutics Delivers A Beat-And-Raise Q2 And A $100 Million Buyback

Summary TG Therapeutics exceeded Q2 Street consensus estimates, with Briumvi net sales of $72.6 million and total revenues of $73.5 million. Positive cash flow achieved one quarter ahead of my expectations, and full-year guidance range raised by $15 million at the mid-point of the range. TG secured a new $250 million credit facility to retire the old one, and it will use $100 million to buy back shares. The phase 1 trial of subcutaneous Briumvi is now enrolling multiple sclerosis patients, with topline data expected in early 2025 and followed by a phase 3 trial starting in mid-2025. Continued positive growth trends of Briumvi and an improving financial position strengthen the long-term outlook for TG Therapeutics. Read the full article on Seeking Alpha

Previsioni di crescita degli utili e dei ricavi

NasdaqCM:TGTX - Stime future degli analisti e dati finanziari passati (USD Millions )
DataRicaviUtiliFlusso di cassa liberoLiquidità dell'operazioneAvg. Numero di analisti
12/31/20281,5785116705575
12/31/20271,2254395444718
12/31/20269402162992497
3/31/2026700462-14-14N/A
12/31/2025616447-25-25N/A
9/30/2025532447-70-70N/A
6/30/202545460-59-59N/A
3/31/202538639-61-61N/A
12/31/202432923-41-41N/A
9/30/2024265-14-28-28N/A
6/30/2024347966868N/A
3/31/2024289412020N/A
12/31/202323413-31-31N/A
9/30/2023190-26-42-42N/A
6/30/202324-176-160-160N/A
3/31/20239-169-167-167N/A
12/31/20223-224-176-176N/A
9/30/20225-239-239-239N/A
6/30/20227-288-272-272N/A
3/31/20228-326-283-283N/A
12/31/20217-348-296-296N/A
9/30/20214-343-261-261N/A
6/30/20212-345-251-250N/A
3/31/20211-319-234-234N/A
12/31/20200-279-215-215N/A
9/30/20200-231-193-193N/A
6/30/20200-206-170-170N/A
3/31/20200-189-162-162N/A
12/31/20190-173N/A-133N/A
9/30/20190-187N/A-136N/A
6/30/20190-159N/A-136N/A
3/31/20190-167N/A-134N/A
12/31/20180-173N/A-129N/A
9/30/20180-150N/A-117N/A
6/30/20180-148N/A-107N/A
3/31/20180-132N/A-100N/A
12/31/20170-118N/A-94N/A
9/30/20170-111N/A-89N/A
6/30/20170-105N/A-81N/A
3/31/20170-92N/A-67N/A
12/31/20160-78N/A-62N/A
9/30/20160-72N/A-57N/A
6/30/20160-61N/A-53N/A
3/31/20160-62N/A-52N/A
12/31/20150-63N/A-45N/A
9/30/20150-64N/A-47N/A
6/30/20150-68N/A-44N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: La crescita prevista degli utili di TGTX ( 15.9% all'anno) è superiore al tasso di risparmio ( 3.5% ).

Guadagni vs Mercato: Si prevede che gli utili di TGTX ( 15.9% all'anno) cresceranno più lentamente rispetto al mercato US ( 16.7% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di TGTX cresceranno, ma non in modo significativo.

Ricavi vs Mercato: Si prevede che il fatturato di TGTX ( 23.5% all'anno) crescerà più rapidamente del mercato US ( 11.7% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di TGTX ( 23.5% all'anno) crescerà più rapidamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di TGTX è previsto essere elevato tra 3 anni

Scoprire le aziende in crescita

7D

1Y

7D

1Y

7D

1Y

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/05/21 06:55
Prezzo dell'azione a fine giornata2026/05/21 00:00
Utili2026/03/31
Utili annuali2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

TG Therapeutics, Inc. è coperta da 18 analisti. 8 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Alec StranahanBofA Global Research
William WoodB. Riley Securities, Inc.
Mayank MamtaniB. Riley Securities, Inc.